RGNX Regenxbio
- 6.950
- -0.560-7.46%
- 7.620
- +0.670+9.64%
Regenxbio News
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Bank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $30
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $22
RBC Capital Reiterates Outperform on Regenxbio, Maintains $35 Price Target
Regenxbio Analyst Ratings
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $36
Buy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval Prospects
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
REGENXBIO Is Maintained at Buy by Chardan Capital
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
Regenxbio Analyst Ratings
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $25
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Stifel Nicolaus Sticks to Its Buy Rating for RegenXBio (RGNX)
A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $18 to $50
Promising Developments in RegenXBio's RGX-202 Program Drive Buy Rating
Morgan Stanley Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $22
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
No Data